Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Eisai Inc.; Exelixis, Inc.; and Merck & Co., Inc.

Community Practice Connections™: Renal Cell Carcinoma Playbook for Urologists: Emerging Strategies Across Lines of Therapy to Optimize Patient Outcomes

Release Date: July 31, 2020
Expiration Date: July 31, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of renal cell carcinoma (RCC), with a forward-looking perspective on how new and novel agents might impact clinical practice. The evolving role of adjuvant therapy for locoregional RCC, risk assessment, new paradigms for treating metastatic RCC, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Acknowledgement of Support

This activity is supported by educational grants from Eisai Inc.; Exelixis, Inc.; and Merck & Co., Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward urologists, oncologists, and researchers interested in the treatment of RCC. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with RCC will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Explain the biologic rationale for the use of targeted agents and immunotherapies as single agents and in combination to treat RCC
  • Evaluate risk stratification criteria, recent clinical trial data, and how emerging adjuvant strategies may further impact the treatment landscape of RCC
  • Review practice-changing and emerging data from clinical trials of systemic therapies for first-line treatment of metastatic RCC
  • Incorporate knowledge of the safety profiles of systemic therapies with best practices to proactively identify and mitigate treatment-related toxicities during treatment planning for patients with metastatic RCC

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Robert A. Figlin, MD, FACP
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology-Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Disclosures: Grant/Research Support: Calithera Biosciences, Exelixis, Merck & Co, Bristol Myers Squibb; Consultant: Apollomics, Arrowhead Pharmaceuticals, Bristol Myers Squibb, Eisai, Merck & Co.

Toni K. Choueiri, MD
Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Institute
Jerome and Nancy Kohlberg Chair and Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: Alexion Pharmaceuticals, Analysis Group, AstraZeneca, Bayer, Bristol Myers Squibb/ER Squibb & Sons LLC, Calithera Biosciences, Cerulean Pharma, Corvus Pharmaceuticals, Eisai, Exelixis, F. Hoffmann-La Roche, Foundation Medicine Inc., Genentech, GlaxoSmithKline, Ipsen, Eli Lilly and Company, Merck & Co, Novartis, Peloton Therapeutics, Pfizer, Prometheus Labs, Roche, Roche Products Limited, Sanofi/Aventis, Takeda, TRACON Pharmaceuticals; Consultant: Analysis Group, AstraZeneca, Alexion Pharmaceuticals, Bayer, Bristol Myers Squibb/ER Squibb & Sons LLC, Cerulean Pharma, Corvus Pharmaceuticals, Eisai, EMD Serono, Exelixis, Foundation Medicine Inc., Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen, Eli Lilly and Company, Merck & Co, National Comprehensive Cancer Network, Novartis, Peloton Therapeutics, Pfizer, Prometheus Labs, Roche, Sanofi/Aventis, Up-to-Date; Other: Honoraria: Alexion Pharmaceuticals, Analysis Group, AstraZeneca, Bayer, Bristol Myers Squibb/ER Squibb & Sons LLC, Cerulean Pharma, Corvus Pharmaceuticals, Eisai, EMD Serono, Exelixis, F. Hoffmann-La Roche, Foundation Medicine Inc., Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen, Eli Lilly and Company, Merck & Co, National Comprehensive Cancer Network, Novartis, Peloton Therapeutics, Pfizer, Prometheus Labs, Roche, Roche Products Limited, Sanofi/Aventis, Up-to-Date.

Daniel J. George, MD
Daniel J. George, MD
Professor of Medicine and Surgery
Co-Director, Duke Cancer Institute Center for Prostate and Urologic Cancers
Director of Genitourinary Oncology
Duke University School of Medicine
Durham, NC

Disclosures: Grant/Research Support: Acerta Pharma, Astellas Pharma, Bayer, Bristol Myers Squibb, Calithera Biosciences, Exelixis, Janssen, Novartis, Pfizer, Sanofi; Consultant: Astellas Pharma, Bayer, Bristol Myers Squibb, Exelixis, Flatiron Health, Janssen, Leidos Biomedical, Merck & Co, Myovant Sciences, Pfizer, Sanofi, UroGPO, UroToday; Speakers Bureau: Bayer, Exelixis, Sanofi; Other: Honorarium: EMD Serono, Ipsen.

Christopher Wood, MD, FACS
Christopher Wood, MD, FACS
Douglas E. Johnson, MD, Endowed Professorship
Professor, Department of Urology
Vice-Chairman, Department of Urology
MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Argos Therapeutics, CoImmune, Mirati Therapeutics, Pfizer; Speakers Bureau: Pfizer; Other: Kidney Cancer Association: Chairman of the Board (No remuneration).

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
3031
Filter By